Cannabis
CBD of Denver Announces Completion of 2019 and 2020 Audits
Denver, Colorado–(Newsfile Corp. – January 10, 2022) – CBD of Denver, Inc. (OTC Pink: CBDD), a cultivator and distributor of CBD and cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe, is pleased to announce the successful completion of its 2019 and 2020 audits.
The audits will be sent to the SEC and OTC Markets and will be available to view on our website. The Company intends to complete an audit of its 2021 results once its fourth quarter numbers become available. To expedite the process, the Company has agreed to fly Kory Kolterman of Fruci & Associates to Switzerland to meet with the Swiss auditing and legal teams. Completion of the 2021 audit will position the Company for uplisting in 2022.
“We are very pleased to announce the 2019 and 2020 audits are complete,” said CEO Marcel Gamma. “We are steadfastly committed to moving forward with our plans to become fully reporting in 2022.”
The company is also planning a board meeting either in January or February 2022, to elect new Directors and take care of other pressing company business.
Follow CBDD on Instagram: @SwissCBDTrading @Rockflowr @CBDofDenver_Inc @SwissGreenGrow @RockflowrRetail
CBD of Denver, Inc., Rockflowr GmbH and Swiss Industry Ventures AG are now also on LinkedIn.
About CBD of Denver, Inc.
CBD of Denver, Inc. (OTC Pink: CBDD) a full-line Cultivator, Distributor of CBD and Cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe. CBD of Denver, Inc. is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis. Through our Rockflowr brands we have built a very strong European customer base by focusing on top quality products and meaningful customer relationships.
Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and you should not place undue reliance on these statements. Any forward-looking statement reflects our current views with respect to future events. We assume no obligation publicly about update or revise these forward-looking statements for any reason.
Contact:
Todd McKnight
RedChip Companies
1-800-733-2447
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109545
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis6 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE6 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis6 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Humboldt6 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis4 days ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III